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Neutralization of IFN-g reverts clinical and
laboratory features in a mouse model of
macrophage activation syndromeGiusi Prencipe, PhD,a Ivan Caiello, BS,a Antonia Pascarella, PhD,a Alexei A. Grom, MD,b Claudia Bracaglia, MD,a
Laurence Chatel, DUT,c Walter G. Ferlin, PhD,c Emiliano Marasco, MD,a Raffaele Strippoli, MD, PhD,d
Cristina de Min, MD,c and Fabrizio De Benedetti, MD, PhDa Rome, Italy, Cincinnati, Ohio, and Geneva, SwitzerlandBackground: The pathogenesis of macrophage activation
syndrome (MAS) is not clearly understood: a large body of
evidence supports the involvement of mechanisms similar to
those implicated in the setting of primary hemophagocytic
lymphohistiocytosis.
Objective: We sought to investigate the pathogenic role of IFN-g
and the therapeutic efficacy of IFN-g neutralization in an
animal model of MAS.
Methods: We used an MAS model established in mice
transgenic for human IL-6 (IL-6TG mice) challenged with LPS
(MAS mice). Levels of IFN-g and IFN-g–inducible chemokines
were evaluated by using real-time PCR in the liver and spleen
and by means of ELISA in plasma. IFN-g neutralization was
achieved by using the anti–IFN-g antibody XMG1.2 in vivo.
Results: Mice with MAS showed a significant upregulation of
the IFN-g pathway, as demonstrated by increased mRNA levels
of Ifng and higher levels of phospho–signal transducer and
activator of transcription 1 in the liver and spleen and increased
expression of the IFN-g–inducible chemokines Cxcl9 and Cxcl10
in the liver and spleen, as well as in plasma. A marked increase
in Il12a and Il12b expression was also found in livers and
spleens of mice with MAS. In addition, mice with MAS had a
significant increase in numbers of liver CD681 macrophages.
Mice with MAS treated with an anti–IFN-g antibody showed a
significant improvement in survival and body weight recovery
associated with a significant amelioration of ferritin, fibrinogen,
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http://dx.doi.org/10.1016/j.jaci.2017.07.021treatment with the anti–IFN-g antibody significantly decreased
circulating levels of CXCL9, CXCL10, and downstream
proinflammatory cytokines. The decrease in CXCL9 and
CXCL10 levels paralleled the decrease in serum levels of
proinflammatory cytokines and ferritin.
Conclusion: These results provide evidence for a pathogenic role
of IFN-g in the setting of MAS. (J Allergy Clin Immunol
2017;nnn:nnn-nnn.)
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Macrophage activation syndrome (MAS) is a term used to
identify hemophagocytic lymphohistiocytosis (HLH) secondary
to rheumatic diseases.1,2 It is a severe and potentially fatal
condition that occurs in the context of rheumatic diseases,
particularly systemic juvenile idiopathic arthritis (sJIA).3 MAS
is classified among the secondary HLHs and shares clinical and
biochemical features with familial or primary hemophagocytic
lymphohistiocytosis (pHLH).4 A cytokine storm appears to be
the driving feature5; the ensuing clinical syndrome is
characterized by high fever, pancytopenia, hyperferritinemia,
hypofibrinogenemia, hepatosplenomegaly, and intravascular
coagulation.6 The triggering mechanism behind pHLH is a defect
in cytotoxicity caused by mutations in genes encoding proteins
required for cytotoxic activity of lymphocytes and natural killer
cells.7 The pathogenesis of MAS is not clearly understood.8
A large body of evidence supports the involvement of
mechanisms similar to those implicated in patients with pHLH.
Indeed, patients with JIA with MAS have been shown to have
transient natural killer cell dysfunction, such as decreased cell
numbers and activity, and reduced perforin expression.9-11
Recently, in patients with sJIA and MAS, genetic studies,
including whole-exome sequencing, identified rare protein-
altering variants in known pHLH-associated genes and new
candidate genes that are possibly involved in intracellular granule
trafficking, further suggesting thatMAS predisposition in patients
with sJIA could be attributed, at least in part, to variants of genes
involved in the cytolytic pathways.12-14 Consistent with these
data, Sepulveda et al15 demonstrated that the accumulation of
monoallelic mutations in HLH-causing genes increases
susceptibility to HLH immunopathology also in mice.
Studies in patients and in animal models of pHLH have
suggested a key role of IFN-g in the pathogenesis of the disease.
Indeed, in a large cohort of children with HLH, highly increased
levels of IFN-g correlated with disease activity have been
reported.16 Moreover, in perforin2/2 mice infected with
lymphocytic choriomeningitis virus, the high amount of IFN-g
produced by CD81 T cells has been demonstrated to be uniquely1
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2 PRENCIPE ET ALAbbreviations usedALT: Alanine aminotransferaseHLH: Hemophagocytic lymphohistiocytosisMAS: Macrophage activation syndromepHLH: Primary hemophagocytic lymphohistiocytosissJIA: Systemic juvenile idiopathic arthritisSTAT1: Signal transducer and activator of transcription 1WT: Wild-typeessential for disease development.17 Similarly, in lymphocytic
choriomeningitis virus/Rab27a–deficient mice, neutralization of
IFN-g has been shown to revert central nervous system
involvement and reduce hemophagocytosis.18 Neutralization of
IFN-g is able to revert hematologic abnormalities also in the
mouse model of HLH secondary to infections, which was
mimicked by repeated stimulation of Toll-like receptor (TLR) 9
on a normal genetic background.19
The aim of this study was to evaluate the pathogenic role of
IFN-g in a mouse model of MAS based on mice transgenic for
human IL-6 (IL-6TG mice).20 We have reported that IL-6TG
mice, after a single administration of TLR ligands, display an
increased fatality rate associated with higher levels of circulating
proinflammatory cytokines and hematologic and biochemical
features typically present in mice with MAS.20 In these mice
MAS is induced by mimicking an acute infection with
administration of a TLR agonist (ie, LPS). This approach
recapitulates what occurs in patients with sJIA: an infection is
the typical trigger ofMAS in the presence of active disease, which
is characterized by high levels of IL-6, which appears to play a
pivotal pathogenic role in the autoinflammation of sJIA.21,22
In this study we investigated whether levels of IFN-g and
IFN-g–inducible chemokines are increased in the setting of MAS
induced by LPS in IL-6TGmice and whether administration of an
anti–IFN-g antibody improves survival and disease parameters.METHODS
Mice and in vivo treatments
The IL-6TG mouse has been described previously.23 Mice between 10
and 14 weeks of age were administered intraperitoneally a single dose
(7.5 or 5 mg/g body weight) of LPS (Escherichia coli serotype 055:B5;
Sigma-Aldrich, St Louis, Mo). For treatment experiments, 100 mg/g body
weight of the anti-mouse IFN-g neutralizing antibody XMG1.2 (BioXCell,
West Lebanon, NH) and of a rat IgG1 isotype-matched control mAb35 (Amer-
ican Type Culture Collection, Manassas, Va) were administered to mice intra-
peritoneally. Mice were maintained under specific pathogen-free conditions
and handled in accordance with the institutional experimental ethics commit-
tee guidelines.Cytokine, ferritin, fibrinogen, and alanine
aminotransferase measurements
Mouse plasma cytokine and chemokine levels were determined by using
MILLIPLEX MAP Multiplex Immunodetection Kits (Merck, Whitehouse
Station, NJ), according to the manufacturer’s instructions. For all analytes, the
lower detection limit was 3.2 pg/mL, and the upper detection limit was 10,000
pg/mL. CXCL9 and CXCL10 levels were further determined by using mouse
Quantikine ELISA KITs (R&D Systems, Minneapolis, Minn). Serum ferritin
and plasma fibrinogen concentrations were determined by using ELISA kits
(ALPCO Diagnostics, Salem, NH, and Abcam, Cambridge, United Kingdom,respectively). Alanine aminotransferase (ALT) levels were determined by
using an enzymatic assay kit (Bioo Scientific, Austin, Tex).RNA isolation and quantitative real-time PCR
Total RNAwas extracted from mouse liver and spleen tissues with TRIzol
(Life Technologies, Grand Island, NY), and cDNA was obtained with the
Superscript Vilo Kit (Invitrogen, Carlsbad, Calif). Real-time PCR assays were
performedwith the TaqManUniversal PCRMasterMix (Applied Biosystems,
Foster City, Calif) and the following gene expression assays: mouse Ifng,
Cxcl9, Cxcl10, Il12a, and Il12b (Applied Biosystems). Gene expression
data were normalized with mouse Hprt (Applied Biosystems) as an
endogenous control. Data are expressed as arbitrary units determined by using
the 22Dct method.Protein extraction and Western blot analysis
Total tissue proteins were extracted with RIPA Buffer (Cell Signaling,
Danvers, Mass). For Western blotting, protein lysates were resolved by using
10% SDS-PAGE. Proteins were then transferred to nitrocellulose membranes
(Amersham Life Sciences, Piscataway, NJ) and probed with antibodies to
phospho-Tyr701 signal transducer and activator of transcription (STAT) 1,
total STAT1, and glyceraldehyde-3-phosphate dehydrogenase (all from Cell
Signaling) by using standard procedures.Histology and immunohistochemical analysis
Livers from mice were drop fixed in neutral buffered formalin and then
processed for paraffin embedding. Sections of 2.5 mm were stained
with hematoxylin and eosin. For immunohistochemical analysis, after moist
heat–induced antigen retrieval with EnVision Flex Target Retrieval Solutions
High pH (DakoCytomation, Glostrup, Denmark), 2.5-mm sections were
incubated with antibody to CD68 (Abcam, Cambridge, United Kingdom)
overnight at 48C. After washing, sections were incubated with appropriate
horseradish peroxidase–conjugated secondary antibodies. Chromogen detec-
tion was carried out with the DAB chromogen kit (DakoCytomation). Nuclei
were counterstained with hematoxylin, followed by dehydration and
mounting. The number of CD681 cells was enumerated in at least 10 fields
for each tissue at 340 magnification.Statistical analyses
Data are presented as means 6 SEMs, unless otherwise indicated. Group
comparisons were performed with the nonparametric Mann-Whitney U test.
The Spearman rank correlation coefficient (r) was calculated to assess
correlations between variables. All statistical analyses were performed with
GraphPad Prism IV software (GraphPad Software, La Jolla, Calif). A P value
of less than .05 was considered statistically significant.RESULTS
IFN-g and IFN-g–inducible chemokine levels are
higher in LPS-challenged IL-6TG mice
Although Ifng mRNA expression levels were not different
between wild-type (WT) and IL-6TG mice in both the liver
(Fig 1, A) and spleen (Fig 1, C) before LPS administration, we
found that they were significantly increased in IL-6TG mice
compared with WT mice at 12 hours after LPS administration
(Fig 1, A and C). Moreover, we found that Cxcl9 mRNA levels
were significantly higher in the liver and Cxcl10 mRNA levels
were significantly higher both in the liver and spleen compared
with those in WT mice (Fig 1, A and C).
Liver and spleen protein lysates were tested by using Western
blotting with a specific antibody for Tyr701-phosphorylated
STAT1, which is known to mediate IFN-g effects, to further
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=FIG 2. Circulating levels of IFN-g–inducible chemokines and proinflammatory cytokines are increased in
LPS-challenged IL-6TG mice. Plasma levels of IFN-g, the IFN-g–inducible chemokines CXCL9 and CXCL10,
and the proinflammatory cytokines IL-1b, IL-6, and TNF-aweremeasured inWT and IL-6TGmice at 18 hours
after challenge with LPS (5 mg/g body weight). Data (means 6 SEMs) are representative of at least 2
independent experiments with at least 3 mice in each group. Statistical analyses were performed with the
1-tailed Mann-Whitney U test: *P < .05, **P < .01, and ***P < .001.
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4 PRENCIPE ET ALevaluate activation of the IFN-g pathway in LPS-challenged
IL-6TG mice compared with WT mice.24,25 We did not detect
Tyr701 phosphorylation of STAT1 before LPS challenge in both
WT and IL-6TG mouse tissues. Tyr701-phosphorylated STAT1
was similarly increased both in the liver (Fig 1, B) and spleen
(Fig 1,D) inWTand IL-6TGmice at 6 hours after LPS challenge.FIG 1. LPS-challenged IL-6TG mice display upregula
expression of Il12a and Il12b. WT and IL-6TG mice wer
different times after the challenge, mice were killed. A
IFN-g–regulated genes Cxcl9 and Cxcl10 were assayed
are expressed as arbitrary units (AU) and obtained aft
Tyr701-phosphorylated STAT1 protein levels were asse
(B) and spleen (D). In Fig 1, B and D, at right, densito
Tyr701-phosphorylated STAT1 in the liver and sple
(n 5 4 or 5 in each group). E and F, mRNA expression
liver (Fig 1, E) and spleen (Fig 1, F). Data in Fig 1, A-F
independent experiments with at least 3 mice in eac
the 1-tailed Mann-Whitney U test: *P < .05, **P < .01, aNotably, although in WT mice phospho-STAT1 levels returned to
baseline at 12 hours after LPS challenge, in IL-6TG mice they
remained markedly higher both in the liver and spleen (Fig 1, B
and D).
Because IL-12, which is produced mainly by classically
activated M1 macrophages,26 is known to stimulate IFN-gtion of the IFN-g pathway and increased mRNA
e challenged with LPS (5 mg/g body weight), and at
and C, mRNA expression levels of Ifng and of the
in the liver (Fig 1, A) and spleen (Fig 1, C). Results
er normalization with the housekeeping gene Hprt.
ssed by means of Western blot analysis in the liver
metric analyses confirmed the increased levels of
en from IL-6TG mice compared with WT mice
levels of Il12a and Il12b were also evaluated in the
(means 6 SEMs), are representative of at least 2
h group. Statistical analyses were performed with
nd ***P < .001.
AB
FIG 3. Presence of dilated sinusoids and infiltration by CD681 macrophages in livers of LPS-challenged
IL-6TGmice.A, Liver sections fromWT and IL-6TGmice at 12 hours after LPS challenge (5mg/g bodyweight)
were stained with hematoxylin and eosin (H&E). Dilated sinusoids populated by mononucleated cells are
indicated by arrows. Representative sections are shown at amagnification of340. B, Representative images
of liver sections from WT and IL-6TG mice stained for total macrophages by using the CD68 antibody at
12 hours after the challenge with LPS (5 mg/g body weight). CD681 cells are indicated by arrows. Scale
bars 5 200 mm. At right, the number of CD681 cells per field was reported. Data (means 6 SEMs) are
representative of at least 2 independent experiments with at least 2 mice in each group. Statistical analyses
were performed with the 1-tailed Mann-Whitney U test: *P < .05.
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IFN-g in an animal model of fulminant MAS,27 we assessed
mRNA expression of the Il12a and Il12b genes, encoding for
the 2 heterologous chains of IL-12 p35 and p40, respectively.
We found that these genes were strongly upregulated in livers
from LPS-challenged IL-6TG mice and significantly higher in
both the liver and spleen in IL-6TG mice compared with WT
mice (Fig 1, E and F). In IL-6TG mouse livers, strong positive
correlations between Il12a and Il12b and Ifng mRNA expression
were also found (r 5 0.93, P 5 .001 and r 5 0.083, P 5 .007,
respectively), further suggesting a possible role for IL-12 in
inducing IFN-g production in the tissue.
When we measured circulating levels of IFN-g, low levels (in
the picogram per milliliter range) were detected, with a trend for
higher levels in LPS-challenged IL-6TGmice compared withWT
mice (Fig 2). These results are consistent with recent observations
demonstrating that production of IFN-g typically occurs in
peripheral tissues.28 In this respect circulating levels of the
IFN-g–inducible chemokines CXCL9 and CXCL10 have been
suggested as possible markers of tissue IFN-g production. Indeed
in LPS-challenged IL-6TG mice, high levels of CXCL9 and
CXCL10 were found in plasma (Fig 2).
Interestingly, we found also that circulating levels of CXCL9
were significantly correlated with liver mRNA levels (18 hours
after LPS administration) of Ifng (r5 0.83, P5 .029) and Cxcl9
(r5 0.89, P 5 .017). Similarly, circulating CXCL10 levels weresignificantly correlated to liver mRNA levels of Ifng (r 5 0.82,
P5 .030) and Cxcl10 (r5 0.89, P5 .017). We also found a tight
correlation between plasma CXCL9 levels and spleen Cxcl9
mRNA levels (r 5 1.0, P 5 .001). The same analyses were
performed in WT mice, and no correlations were observed.
Furthermore, and consistent with previously published data at
6 hours from LPS challenge,20 at 18 hours, levels of
proinflammatory cytokines, including IL-1b, TNF-a, and IL-6,
were markedly higher in LPS-challenged IL-6TGmice compared
with WT mice (Fig 2).
Altogether, our data show that in the mouse model of MAS,
Ifng expression is increased, the STAT1-mediated IFN-g pathway
is upregulated, and the IFN-g–inducible chemokines are
upregulated locally and systemically. The significant correlation
between Ifng and chemokine transcript levels in peripheral tissues
and chemokine levels in the blood supports the conclusion that
circulating levels of IFN-g–inducible chemokines reflect tissue
activation of the IFN-g pathway, as well as tissue production of
IFN-g–inducible chemokines.
Incidentally, liver hematoxylin and eosin staining did not
reveal major abnormalities in hepatocytes. However, dilated
sinusoids populated by mononucleated cells were observed in
LPS-challenged IL-6TG mice but not in WT mice (Fig 3, A).
Macrophages are most probably key early cells in the
pathogenesis of MAS; indeed, immunohistochemical analyses
showed a markedly higher number of CD68 (a panmacrophage
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FIG 5. Inmice treatedwith the anti–IFN-g antibody (Ab), circulating levels of
proinflammatory cytokines are downmodulated. IL-6TG mice were
challenged with LPS (5 mg/g body weight), and 12 hours after the challenge,
mice were treated with the IFN-g neutralizing antibody XMG2.1 (100 mg/g
body weight) or with the mAb35 control antibody. Eighteen hours after
treatment with antibodies, mice were killed, and levels of CXCL9 and
CXCL10 (A) and proinflammatory cytokines (B), including IL-1b, IL-6, and
TNF-a, were assayed in plasma samples collected at the time of death.
Data (means 6 SEMs) are representative of at least 2 independent
experiments with at least 3 mice in each group. Statistical analyses were
performed with the 1-tailed Mann-Whitney U test: *P < .05 and **P < .01.
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WT mice (Fig 3, B), suggesting a role for macrophages in the
development of the disease in IL-6TG mice.Neutralization of IFN-g improves survival, body
weight recovery, and laboratory parameters in
LPS-challenged IL-6TG mice
Having demonstrated that the IFN-g pathway is upregulated in
murine MAS induced by LPS challenge in IL-6TG animals, the
effect of neutralization of IFN-g was tested by administering an
anti–IFN-g antibody. After control antibody administration, all
mice challenged with a dose of LPS known to be lethal in 100% of
the animals (7.5 mg/g body weight) died within 4 days, whereas
70% of mice treated with the anti–IFN-g antibody survived
(Fig 4,A). Similarly, after control antibody administration, 5 of 10
mice challenged with a dose of LPS known to be lethal in 50% of
animals (5 mg/g body weight) died within 4 days, whereas all
mice treated with the anti–IFN-g antibody survived (Fig 4, B).FIG 4. Treatment with a neutralizing anti–IFN-g antibod
parameters of MAS in LPS-challenged IL-6TGmice. IL-6
of LPS (A) or with 5 mg/g body weight of LPS (B) at day 0
with the IFN-g neutralizing antibody XMG2.1 (100 mg/g
and were monitored for survival. Survival rates were
group). The Fisher exact test was performed. C-F, IL-
weight) at day 0 and treated, as previously described, w
ical and laboratory parameters were evaluated: body w
plasma fibrinogen (Fig 4, E), and plasma ALT (Fig 4, F) l
presented with last observation carried forward fo
(means6 SEMs) are representative of at least 2 indepen
Statistical analyses were performed with the 1-tailed MNo additional deaths occurred in the following days in both
groups of mice and in both experiments (data not shown).
In mice injected with 5 mg/g LPS, anti–IFN-g treatment
significantly improved body weight recovery, with animals
reaching their baseline weight within 3 days (Fig 4, C). After
12 hours from LPS administration, a marked increase in
ferritin levels was observed, which is consistent with previous
data.20 Although ferritin levels did not change in control
antibody–treated IL-6TG mice, a sharp decrease was observed
in mice treated with the anti–IFN-g antibody (Fig 4, D). After
LPS administration, levels of plasma fibrinogen, an additional
laboratory feature of MAS, were significantly lower in IL-6TG
mice compared with those in WT mice (mean 6 SD,
4229 6 1885 vs 6654 6 1526 mg/mL, P 5 .01), suggesting
increased intravascular coagulation activation in this animal
model. We found that in LPS-challenged IL-6TG mice
fibrinogen levels were significantly higher in mice treated with
the anti–IFN-g antibody compared with mice treated with the
control antibody (Fig 4, E).
To biochemically evaluate liver involvement, we measured
ALT levels. As previously demonstrated, we did not observe a
significant difference in circulating ALT levels between LPS-
challenged IL-6TG and WT mice both at baseline and 12 hours
after LPS (mean6 SD: basal levels, 13.586 6.8 vs 12.26 10.07
U/L; 12 hours after LPS administration, 40.2 6 21.24 vs
38.7 6 15.30 U/L). In IL-6TG mice after administration of the
anti–IFN-g antibody, ALT levels were significantly reduced
compared with those in control-treated animals (Fig 4, F).IFN-g–inducible chemokines and proinflammatory
cytokines are downregulated in mice treated with
the anti–IFN-g antibody and are related to changes
in ferritin levels during effective treatment
In anti–IFN-g antibody–treated IL-6TG mice plasma levels of
CXCL9 and CXCL10 were markedly lower than those of mice
treated with control antibody (Fig 5, A). Moreover, plasma levels
of IL-1b, IL-6, and TNF-a, 3 classical proinflammatory
cytokines, were significantly lower in anti–IFN-g antibody–
treated than in control antibody–treated mice (Fig 5, B). Finally,
in LPS-challenged mice treated with the control and the
anti–IFN-g antibody, lower circulating levels of CXCL9 and
CXCL10 were significantly associated with lower levels of
IL-6, IL-1b, and TNF-a (Fig 6, A), as well as with lower serum
ferritin levels (Fig 6, B and C). These results support the
conclusion that a decrease in IFN-g activity, as estimated by the
decrease in CXCL9 and CXCL10 levels, is related to downstream
events, such as inflammatory cytokine levels and clinical
parameters of disease.y (Ab) improves survival and clinical and laboratory
TGmice were challenged with 7.5 mg/g body weight
, and 12 hours after the challenge, mice were treated
body weight) or with the control antibody mAb35
determined every day for 4 days (n 5 10 mice per
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eight variation (Fig 4, C) and serum ferritin (Fig 4, D),
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FIG 6. Circulating levels of the IFN-g–inducible chemokines CXCL9 and CXCL10 are correlated to changes in
proinflammatory cytokine and ferritin levels during effective treatment in IL-6TG mice. IL-6TG mice were
challenged with LPS (5 mg/g body weight), and 12 hours after the challenge, mice were treated with the
IFN-g neutralizing antibody XMG2.1 (100 mg/g body weight; solid squares) or with the mAb35 control
antibody (open squares). Eighteen hours after treatment with antibodies, mice were killed, and levels of
CXCL9 and CXCL10 were measured in plasma and related to circulating levels of the proinflammatory
cytokines IL-6, IL-1b, and TNF-a (A), as well as to serum ferritin levels (B and C). The Spearman rank
correlation coefficient was calculated (r) to assess correlations between variables.
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Although several observations in murine models and indirect
evidence in patients point to a pivotal pathogenic role of IFN-g in
patients with pHLH,17,18 limited data are available on its role in
pathogenesis of the different forms of secondary HLH. In this
study we used a murine model of MAS in which clinical and
laboratory features of MAS are induced by administration of a
TLR ligand in IL-6 transgenic mice.20 We found that IL-6TG
mice challenged with LPS display upregulation of the IFN-g
pathway, as shown by higher mRNA expression levels of Ifng,
higher levels of phospho-STAT1 and the IFN-g–inducible genes
Cxcl9 and Cxcl10 in the liver and spleen, and higher levels of
circulating CXCL9 and CXCL10. Moreover, we found that
treatment of IL-6TGmice with an anti–IFN-g antibody improved
survival, body weight, and laboratory parameters. Finally,
neutralization of IFN-g led also to a marked decrease in
circulating levels of CXCL9 and CXCL10, chemokines typically
induced by IFN-g, as well as of the downstream inflammatory
cytokines TNF-a, IL-6, and IL-1b.
Despite the evidence that in normal mice systemic
overexposure to high levels of IFN-g is sufficient to drivecytopenias and hemophagocytosis in a STAT1-dependent
manner,29 data on the role of IFN-g in models of secondary
HLH are scarce and in part contradictory. In a model of HLH
secondary to infections induced by TLR9-repeated stimulation,
on a normal genetic background and in the absence of underlying
disease, an important pathogenic role for IFN-g has been
reported.19 Moreover, by using IFN-g–overexpressing mice,
IFN-g has been identified as a mediator of systemic inflammatory
disease, supporting the hypothesis that there is a critical threshold
of IFN-g that, when achieved either locally in tissues or
systemically, drives the development of an autoinflammatory-
like disease, interestingly with high ferritin levels.30 In apparent
contrast, immune stimulation of IFN-g knockout mice with
Freund complete adjuvant produces a systemic inflammatory
disease that includes features of sJIA, as well as MAS, such as
anemia, increased numbers of immature blood cells, increased
serum levels of IL-6, hemophagocytosis, and defective natural
killer cell cytotoxicity; it is noteworthy that cytopenias and
hyperferritenemia were not demonstrated in this model.31 Canna
et al27 demonstrated that in mice treated with an IL-10 receptor
blocking antibody and a TLR9 agonist, fulminant MAS and
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IFN-g, they had immunopathology and hemophagocytosis
comparablewith that seen inWTmice but did not become anemic
and had greater numbers of splenic erythroid precursors.27
Similarly, in a mouse model of HLH associated with
cytomegalovirus-related sepsis, IFN-g knockout mice display a
more severe spectrum of the disease,32 therefore suggesting a
protective role for IFN-g. The interpretation of these results,
which appear to be at least in part contradictory, might be
particularly difficult because of compensatory mechanisms
secondary to a lack of or increased expression of IFN-g since
prenatal age in these animal models.
Although these approaches provide a wealth of information on
the pathophysiology of hyperinflammation, these compensatory
mechanisms make it difficult to directly extrapolate the findings
into a therapeutic approach in subjects with a ‘‘normal’’ immune
response. Indeed, recently, 2 unrelated patients with novel
mutations in IFN-g receptors, which is highly suggestive of
functional receptor deficiency, have been described with a clinical
presentation that closely resembled that of HLH in the context of
overwhelming mycobacterial infections (with associated herpes
virus infections).33 This observation has suggested that
IFN-g–independent pathways can contribute to the development
of the clinical syndrome HLH or at least to some of the
characteristic features.
As previously mentioned, animal models of pHLH caused by
deletion of the genes involved in pHLH on an otherwise normal
immune response have unequivocally demonstrated a pivotal
pathogenic role of IFN-g. We have used a model in which MAS
clinical and laboratory features are triggered in animals with high
levels of circulating human IL-6 since early phases of life (not
prenatally), with a normally regulated expression of IFN-g.20 Our
model has similarities with MAS development in patients with
sJIA, whereMAS is typically triggered by acute infections during
an underlying case of active sJIA, which is typically characterized
by increased IL-6 levels.
Our data show high mRNA expression of IFN-g associated
with high Il12a and Il12b mRNA expression in the liver and
spleen, suggesting that IL-12 might be at least one of the factors
involved in increased production of IFN-g in the presence of high
in vivo levels of IL-6. Overexpression of IFN-g is biologically
relevant, as shown by the prolonged phosphorylation of STAT1
in the liver and spleen and by the marked upregulation of liver
and spleen expression and plasma levels of IFN-g–inducible
chemokines. These observations in the liver and spleen, which
are target tissues in the setting of MAS, appear to complement
observations in patients with secondary HLH34 and MAS. Billiau
et al35 showed the presence of IFN-g–producing activated CD81
lymphocytes in 4 liver biopsy specimens of patients with
secondary HLH, including 1 patient with MAS. More recently,
high levels of IFN-g and CXCL10 in the sera of 5 patients with
HLH, 3 of them with MAS, have also been reported.36 Recently,
we found high circulating levels of IFN-g and IFN-g–inducible
chemokines in 20 patients with active MAS but not in patients
with active sJIA without MAS.37 It should be noted that gene
expression profile studies of PBMCs of patients with active
sJIAwith or without MAS did not show an IFN-g signature.38-40
However, although gene expression profile studies on PBMCs
reveal events that occur in peripheral blood, our animal data in
the liver and spleen support the hypothesis that, in patients with
MAS, marked production of IFN-g and IFN-g–inducible proteinsoccurs first in diseased tissues, after which proteins leak into
peripheral blood. Supporting this hypothesis, we found that in
LPS-challenged IL-6TG mice there was a significant correlation
of circulating levels of CXCL9 and CXCL10 with liver/spleen
mRNA levels of Cxcl9 and Cxcl10 and, more importantly, with
tissue mRNA levels of Ifng. Notably, Put et al36 reported evident
expression of the IFN-g–inducible proteins indoleamine
2,3-dioxygenase and CXCL10 in 1 lymph node biopsy specimen
from 1 patient with sJIA with MAS. Furthermore, some of us
demonstrated in the model of HLH secondary to infection
induced by repeated TLR9 stimulation that total IFN-g levels
produced in tissues are 500- to 2000-fold higher than those
measured in blood and identified the spleen and liver as major
sites of IFN-g production.28 These results are consistent with
our finding of a trend for increased circulating levels of IFN-g
in our mice with MAS. Together, these observations in patients
with MAS and in MAS animal models support the hypothesis
that IFN-g production is markedly increased, that high IFN-g
production is biologically relevant, and that overactivation of
the IFN-g pathway appears to occur in peripheral tissues, which
are typically involved by the disease, such as the liver and spleen.
We also demonstrated the pathogenic role of IFN-g in the
murine MAS model. Treatment with an anti–IFN-g antibody led
to a significant increase in survival and reverted clinical and
laboratory features of MAS, including body weight loss and
ferritin, ALT, and fibrinogen levels. Furthermore, neutralization
of IFN-g led to a significant decrease in levels of classical
downstream proinflammatory cytokines. Interestingly, we found
that in LPS-challenged mice circulating CXCL9 and CXCL10
levels were significantly related to IL-1b, IL-6, TNF-a, and
ferritin levels. Further supporting the relevance of IFN-g
neutralization, we showed that the extent of change in upstream
events (ie, CXCL9 and CXCL10 levels) is related to the extent of
the decrease in downstream events, such as levels of
proinflammatory cytokines, or even more so, levels of ferritin, a
classical laboratory parameter of disease activity in clinical
practice. Consistent with these data in mice, we found that in
patients with MAS sampled longitudinally during effective
traditional treatment, circulating levels of both CXCL9 and
CXCL10 paralleled the decrease in ferritin levels during the
progressive clinical improvement (data not shown). Data in
animals and human subjects suggest also that serum levels of
CXCL9 and possibly CXCL10, because they reflect tissue
production of IFN-g, might represent additional biomarkers of
disease activity in the setting of MAS. Their relative value
compared with standard biochemical parameters, such as ferritin
levels, in identifying patients in the early stages of MAS before it
progresses to its life-threatening stage should be investigated in a
larger number of patients, possibly in a multicenter study.
Our experimental model of MAS has the limitation of having
short duration (death occurs in 2-4 days after LPS administration),
therefore representing an acute model of the disease useful to
study early stages (ie, induction mechanisms) of the disease. In
contrast, we cannot evaluate improvement in late events, such as
tissue infiltration and damage (fibrosis/collagen deposition).
Nevertheless, this MAS model has allowed us to deepen our
understanding of the early events that are upstream of the disease
development. Indeed, we showed that in livers of micewithMAS,
the number of CD681 macrophages and expression of IL-12,
mainly produced by M1 macrophages, was increased compared
with that in WT mice.
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IL-6 in inducing increased macrophage infiltration and
upregulation of Il12 expression in the liver and demonstrated
the pivotal role of IFN-g in a murine model of MAS. Our data,
together with those obtained in animal models of pHLH and of
HLH secondary to infections,17-19,28 support the hypothesis that
HLH forms of different origin share a common inflammatory
effector pathway involving IFN-g. Our results also have
significant implications for the treatment of patients with MAS.
Encouraging preliminary efficacy and safety data of the phase 2
clinical trial in patients with pHLH with the anti–IFN-g mAb
NI-0501 have been reported recently.41
Key messages
d In a murine model of MAS, the IFN-g pathway is
markedly activated in the liver and spleen in the early
phase of the disease.
d IFN-g neutralization ameliorates survival and clinical
and laboratory features of MAS.
d Tissue and circulating levels of the IFN-g–inducible
chemokines CXCL9 and CXCL10 reflect activation of
the pathway and might represent biomarkers of disease
in human patients with MAS.REFERENCES
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